Pfizer Vaccine Ingredient PEG May Cause Anaphylaxis
April 8, 2022 • by DailyClout DailyClout
Pfizer Vaccine Ingredient PEG May Cause Anaphylaxis
Key messages:
- The Pfizer/BioNTech COVID-19 vaccine can cause severe anaphylaxis of unknown cause
- Here, we show polyethylene glycol (PEG) allergy caused one of the first cases of anaphylaxis to the Pfizer/BioNTech COVID-19 vaccine
- Allergy skin prick testing with polyethylene glycol triggered anaphylaxis, highlighting the importance of safety procedures during investigation
View on Campaigns
Phizer, Moderna and government regulators knew full well of the risk of severe reactions to the PEG content in their vaccines. The scientific community identified the problems with PEG years ago. The fact that 72% of our population have preexisting antibodies to PEG, with 8% of that group having elevated levels putting them at high risk for anaphylaxis was reported some time ago. MODERNA’s scientists wrote about the risk. Their SEC filings highlighted the risk. I wrote everyone in the regulatory chain about the risk and the science. Robert Kennedy Jr. wrote regulators about the risk. Lyn Redwood and I wrote several papers identifying the risk. I wrote my Congressman about the risk. Then the injections were rolled out and, low and behold, cases of anaphylaxis occurred at seemingly higher rates than anticipated (1.3 in a million). The regulators feigned ignorance as to the most likely cause. They said they were going to do a study to get to the bottom of it, but the study they stood up excluded people with PEG reactions, this when one of the study leads said the most likely cause is PEG. Then follow on studies showed an incidence of anaphylaxis of between 247-300 per million, way over the advertised 1.3 per million. Other British studies confirmed anaphylaxis to injection PEG content. There are other more serious adverse reactions identified to these injections, but the one which can be absolutely proven the manufacturers and regulators knew full well about, and admittedly took no risk mitigation steps for, is the hypersensitivity to PEG the population risk of which was well documented and well know. Apart from anaphylaxis, the fact that 72% of the population had preexisting antibodies to an injection constituent presented a huge risk to effectiveness as the body would try to clear the injection rapidly, leading to a decreased neutralizing antibody response. This exacerbates the risk of Antibody Enhancement of Disease. The clinical trials specifically excluded participants with sensitivities to any injection constituents, so there was no data from the trials to indicate effectiveness in the population 72% of which had preexisting PEG antibodies. Israeli and British data now show that 90% of those hospitalized are “vaccinated.” Increasingly the data is showing the injections make one more susceptible to infection and do not prevent worse outcomes. We may be seeing ADE now.